US › Healthcare

Neuraxis, Inc. (NRXS)

US · Healthcare · Biotechnology

$7.01+6.37%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$1.6M

Revenue YoY

+79.5%

Net profit

$-1.8M

Profit YoY

+22.7%

EPS

$-0.18

EPS estimate

$-0.24

Net margin

-109.5%

EPS came in at -0.18 against a street estimate of -0.24 — a beat of 25.8%.

Key statistics

Market cap

$78.0M

Forward P/E

0.0

P/B

13.58

Book value

$0.50

EPS (TTM)

$-0.80

52-week high

$9.33

52-week low

$2.20

50-day MA

$6.97

200-day MA

$5.53

Beta

1.42

Analyst view

Analysts rate Neuraxis, Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.00.

Shareholding

Insiders

19.82%

Institutions

22.51%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Neuraxis, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.